- Home
- SPRO vs NCTY Comparison
SPRO vs NCTY Comparison
Compare SPRO & NCTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- NCTY
- Stock Information
- Founded
- SPRO 2013
- NCTY 1999
- Country
- SPRO United States
- NCTY China
- Employees
- SPRO N/A
- NCTY N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- NCTY Business Services
- Sector
- SPRO Health Care
- NCTY Consumer Discretionary
- Exchange
- SPRO Nasdaq
- NCTY Nasdaq
- Market Cap
- SPRO 121.0M
- NCTY 121.2M
- IPO Year
- SPRO 2017
- NCTY 2004
- Fundamental
- Price
- SPRO $1.90
- NCTY $10.31
- Analyst Decision
- SPRO Buy
- NCTY
- Analyst Count
- SPRO 4
- NCTY 0
- Target Price
- SPRO $5.00
- NCTY N/A
- AVG Volume (30 Days)
- SPRO 391.2K
- NCTY 55.6K
- Earning Date
- SPRO 08-12-2025
- NCTY 01-01-0001
- Dividend Yield
- SPRO N/A
- NCTY N/A
- EPS Growth
- SPRO N/A
- NCTY N/A
- EPS
- SPRO N/A
- NCTY N/A
- Revenue
- SPRO $48,576,000.00
- NCTY $15,305,175.00
- Revenue This Year
- SPRO N/A
- NCTY N/A
- Revenue Next Year
- SPRO N/A
- NCTY N/A
- P/E Ratio
- SPRO N/A
- NCTY N/A
- Revenue Growth
- SPRO N/A
- NCTY N/A
- 52 Week Low
- SPRO $0.51
- NCTY $6.28
- 52 Week High
- SPRO $3.22
- NCTY $20.59
- Technical
- Relative Strength Index (RSI)
- SPRO 39.50
- NCTY 61.03
- Support Level
- SPRO $1.91
- NCTY $9.06
- Resistance Level
- SPRO $2.18
- NCTY $10.88
- Average True Range (ATR)
- SPRO 0.10
- NCTY 0.70
- MACD
- SPRO 0.01
- NCTY 0.17
- Stochastic Oscillator
- SPRO 19.18
- NCTY 79.42
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.